If confirmed by future large prospective, randomized, controlled studies, inhibiting the IL6-STAT3 pathway [33] may be a valuable addition to trastuzumab treatment of primary HER2-positive breast cancer, especially those that are PTEN deficient. Here, STAT3 is linked to breast cancer.